Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Suspended
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Saroglitazar (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Zydus Discovery DMCC
  • Most Recent Events

    • 01 Feb 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 16 Jul 2018 Planned End Date changed from 30 Dec 2018 to 31 Dec 2018.
    • 16 Jul 2018 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top